1276 (1276) Fair Value & Analysis

Healthcare · Market cap HK$384B

1 1276 1276 · HK

PriceHK$57.85

Fair ValueHK$29.84

Upside-48.4%

Quality57/100

Evidence: High Range HK$22.38 – HK$43.72

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −3.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$52.45 – HK$93.77 · fair‑value band HK$22.38 – HK$43.72 · the HK$57.85 price screens above the HK$29.84 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1276 (1276) currently trades at HK$57.85, while our model-based Fair Value estimate is HK$29.84 — implying the stock looks roughly 48.4% overvalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 1276 generated revenue of HK$32.6B at a net margin of 24.9%. Revenue grew 13.0% year over year. It earns a return on equity of 14.5%. The balance sheet holds a net cash position of HK$45.5B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$32.6B

Revenue growth (YoY) +13.0%

Net margin 24.9%

Return on equity 14.5%

Free cash flow HK$9.2B FY2025

P/E ratio 41.0

More key figures

Operating margin 31.6%

EPS (TTM) HK$1.35

Dividend yield 0.3%

EPS growth (YoY) +13.3%

Net cash HK$45.5B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1276 reported revenue of HK$35.2B in FY2025 versus HK$31.0B in FY2021, a compound +3.2%/yr. Reported net income was HK$8.6B in FY2025, compounding +12.0%/yr from FY2021.

Revenue +3.2%/yr

FY21 HK$31.0B

FY22 HK$24.2B

FY23 HK$25.3B

FY24 HK$29.8B

FY25 HK$35.2B

Net income +12.0%/yr

FY21 HK$5.5B

FY22 HK$4.4B

FY23 HK$4.8B

FY24 HK$6.7B

FY25 HK$8.6B

Is 1276 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥26.59	-46%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%
Swedish Orphan Biovitrum AB SOBI	kr 435.00	kr 285.77	-34%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1276 (1276) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$29.84 versus a price of HK$57.85 — about −48% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1276?

Our model-based fair value for 1276 is HK$29.84 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$57.85.

What is the quality score of 1276?

1276 has a Quality Score of 57/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1276 (1276)?

1276 reported trailing-twelve-month revenue of about HK$32.6B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1276?

The net profit margin of 1276 is about 24.9%, meaning it keeps roughly 24.9% of revenue as net income. Based on the latest reported figures.

Does 1276 pay a dividend?

1276 currently shows a dividend yield of about 0.34% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.